S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:MBRX

Moleculin Biotech Stock Forecast, Price & News

$1.07
+0.11 (+11.46 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.97
Now: $1.07
$1.10
50-Day Range
$0.77
MA: $0.87
$1.02
52-Week Range
$0.32
Now: $1.07
$1.97
Volume9.52 million shs
Average Volume3.26 million shs
Market Capitalization$66.84 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech logo

MarketRank

Overall MarketRank

1.24 out of 5 stars

Medical Sector

767th out of 1,926 stocks

Pharmaceutical Preparations Industry

387th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBRX
CUSIPN/A
Phone713-300-5160
Employees11

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.34 per share

Profitability

Net Income$-13,200,000.00

Miscellaneous

Market Cap$66.84 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable
$1.07
+0.11 (+11.46 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

How has Moleculin Biotech's stock price been impacted by COVID-19 (Coronavirus)?

Moleculin Biotech's stock was trading at $0.5051 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MBRX shares have increased by 111.8% and is now trading at $1.07.
View which stocks have been most impacted by COVID-19
.

Is Moleculin Biotech a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Moleculin Biotech stock.
View analyst ratings for Moleculin Biotech
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Moleculin Biotech?

Wall Street analysts have given Moleculin Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Moleculin Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Moleculin Biotech's CEO?

1,448 employees have rated Moleculin Biotech CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Moleculin Biotech's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Moleculin Biotech's next earnings date?

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Moleculin Biotech
.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its quarterly earnings data on Thursday, November, 19th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.03.
View Moleculin Biotech's earnings history
.

What price target have analysts set for MBRX?

2 Wall Street analysts have issued 1 year price targets for Moleculin Biotech's stock. Their forecasts range from $2.00 to $3.00. On average, they expect Moleculin Biotech's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 133.6% from the stock's current price.
View analysts' price targets for Moleculin Biotech
or view Wall Street analyst' top-rated stocks.

Who are some of Moleculin Biotech's key competitors?

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the following people:
  • Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 60, Pay $861.57k)
  • Mr. Jonathan P. Foster, Exec. VP & CFO (Age 56, Pay $508.19k)
  • Dr. Donald H. Picker, Chief Scientific Officer (Age 74, Pay $417.19k)
  • Dr. Waldemar Priebe Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard FACP, M.D., F.A.C.P., Chief Medical Officer of Annamycin (Age 68)
  • Dr. Sandra L. Silberman, Chief Medical Officer of New Products (Age 64)
  • Ms. Jacqueline Northcut, Consultant (Age 58)
  • Mr. Louis Ploth Jr., Independent Advisor (Age 66)

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.07.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $66.84 million. The company earns $-13,200,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Moleculin Biotech employs 11 workers across the globe.

What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is www.moleculin.com.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.